In silico and *in vitro* anti-cancer Study of *Coleus zeylanicus* Leaves Extract on PBMC and MCF7 cell lines - A potential reservoir of Bioactive molecules

Lakshmi M.^{1*}, Nandagopal S.² and Ganesh Kumar A.³

Department of Biotechnology, Sathyabama, Institute of Science and Technology, Chennai – 600119, INDIA
 Department of Botany, Government College of Arts and Science, Hosur - 635110, Tamil Nadu, INDIA
 Department of Microbiology, Hindustan College of Arts and Science, Padur, OMR, Chennai - 603 103, INDIA
 *lakshmiprabhu95@gmail.com

Abstract

Coleus zeylanicus is one of the plant species belonging to the family Lamiaceae with many bioactive characteristics and well-known bio-therapeutic applications. In this work, bioactive components of chloroform and ethanol leaf extracts of Coleus zeylanicus were analysed by GC-MS. The GC-MS chromatogram represents the presence of 12 phytochemical compounds. Further, the leaf extracts were investigated for in-vitro anti-cancer activity. MTT assay was experimented to understand the cytotoxicity ability of C.zeylanicus extract MCF7 and PBMC cells. The IC50 values of the extracts were found to be 64.81 ± 0.57 µg/ml and 87.92 ± 0.86 µg/ml respectively.

Subsequently, the identified 12 compounds were docked against VEGF Receptor (1Y6A), BCL-2 (5JSN) and VEGF factor D (2XV7) in order to explore its inhibitory action by in silico anti-cancer property. In this study the phytochemical compounds were analysed by GC-MS and for in-vitro anti-cancer activity of this plant species. The result of this study may lead to create a path for of novel anti-cancer drugs development.

Keywords: *Coleus zeylanicus*, GC-MS, PBMC and MCF7 cells, *in silico* anti-cancer.

Introduction

Coleus zeylanicus is a member from Lamiaceae referred in India as "Iruveli" or "Karuver³⁹. The plant species has been reported in past decades for its therapeutic efficiency against digestive problems like abdominal discomfort and inflammation¹. This plant is reported to cause astringent, common cold, fever, asthma, small pox, nausea, diarrhea, dysentery, stomach ulcer, dental infections, eye infections and infections caused by worms³. Diarrhea is treated and cured with the herbal juice extracted from the leaves and stems of *C.zeylanicus* along with honey^{1,5}. It also has chronic, diaphoretic, diuretic, cholagogue and acute congestion of liver and biodegradable micro-biocides⁷.

Cancer is considered to be one of the most life threatening and fatal diseases in the world. It has been reported that there are more than 100 types of cancer. Cancer is considered to be third leading cause for death in the world¹³. It is reported that 12.5% of the population died due to cancer. The mortality rate of cancer is very high, but many advancements came in treating the cancer and understanding its biological pathway at the cellular level⁵. The most common cancer diagnosed in women is breast cancer. South central Asian countries were reported to have highest incidence of breast cancer. Breast cancer is considered to be the common and malignant form of cancer in women.

Mostly 43.7% of breast cancers can be detected at earlier stage³. Research has been conducted to search for an alternative and efficient drug produced naturally by using the phytocompounds obtained from plants to slow down, prevent and also to avoid cost of chemotherapeutic agents, side effects and anticancer drugs. Medicinal plants can be used as an alternate source in providing an efficient therapeutic drug for treating cancer as there are more than 50% of cancer agents identified in plants.^{2,6}

Various research investigations in accordance with cancer have been reported from various plants with medicinal value to find new bioactive molecules that have lesser side effects. With the above mentioned point, a study has been done to evaluate the anti-cancer activity by both *in vitro* and *in silico* approach to help Indian traditional way of treatment to combat cancer fatality.

Material and Methods

Extraction procedure: The extracts were prepared by collecting the leaves from the plant *Coleus zeylanicus*; the leaves were washed thoroughly with distilled water and kept for shade drying. After drying, the samples were powdered and refrigerated at 4°C until further use. 10% (w/v) of crude fresh extract was dissolved in chloroform and ethanol and kept for 24 hrs with intermittent shaking. After 24 hr the extracts were filtered with Whatmann filter paper no. 1 and the obtained clear filtrate was evaporated till it becomes dry to form chloroform extracts and then refrigerated at 4°C for further study.

GC-MS spectrum: In recent times, GC-MS has been employed as ideal method for the detection of compounds in various medicinal plants extracts in order to explore its bioactive compounds present in various plants having medicinal values. Chloroform and ethanol leaf extracts of *C. zeylanicus* were analysed. The GC-MS chromatogram of chloroform and ethanol leaf extracts of *C. zeylanicus* represented a total of 14 peaks corresponding to the compounds presents in the leaf extracts. Retention time, peak area (%), height (%) and mass spectral fragmentation fingerprints pattern to that of available known compounds were cited in the National Institute of Standards and Technology (NIST) library. Molecular docking study was further taken to screen the lead compounds with anti-cancer activity before proceeding to *in vitro* anti cancer study.

In silico anti-cancer study by molecular docking

Protein and Ligands preparation: Targets were identified as supported property of neoplastic cell escaping apoptosis, initiation of cancer signals by growth factors. Three protein targets were selected for studying interaction of small compounds that have potential to bind and reverse the function of those targets. *In silico* analysis of the identified compounds from the plant *Coleus zeylanicus* was studied for binding interaction against BCL2 which is an apoptic regulator. The three-dimension structural information about the protein targets was retrieved from protein data bank. All the heteroatoms and bounded ligands were far away from the native structure for molecular docking study.

The identified phytochemical compounds were chosen as ligands and their 3-D structure was retrieved from Pubchem NCBI database in SDF format from which they were converted to PDB format using Open Babel software. The binding efficiency of ligands was performed using AutoDock 4.2 software. Algorithm used for searching best conformers was Genetic Algorithm (GA). Maximum conformers for every compound interaction were set to 10. Results evaluated supported best conformer formed out of 10.

Compounds purification and Structure elucidation: Column chromatography was used for purification of ethanol and chloroform leaf extract on a packed silica gel (100-200 mesh - Merck) and compounds were eluted with mixture of solvents by focusing solvent polarity increasing parameters with chloroform, ethyl acetate, ethanol, methanol and distilled water in the used ration of 90:10, 80:20, 70:30, 50:50, 30:70, 20:80, 10:90. 5 fractions were collected. The isolated compound yield obtained was 25 mg in chloroform. Thin layer chromatography was used to predict the number of compounds in the collected fractions. The collected fractions were loaded on silica gel (0.2 mm thickness) 60 F_{254} coated aluminium plate with a eluting solvents ethyl acetate:methanol (2:1).

The TLC plates were derivatized by immersing the plate in vanillin sulfuric acid (1%) and then the plate heated on 105 °C for color formation. All the five collected fractions were analysed for compound structure elucidation using NMR method (Bruker 400 MHz, CD₃OD). In fraction 4, the three compounds were predicted by following ¹H NMR method.

In vitro **anti-cancer study:** The anti-cancer activity was designed on PBMC and breast cancer cell line MCF-7 received from National Centre for Cell Sciences, Pune, India. The cell lines were cultured in Dulbeco's modified

eagle medium (DMEM) and supplemented with 10% heat inactivated FBS, 2mM L-glutathione, penicillin (100 IU/ml), streptomycin (100 μ g/ml) and amphotericin B (5 μ g/ml) in humidified atmosphere with supply of 5% CO₂ at 37°C until confluent. The cells were typs/850*963-[.3nized with trypsin EDTA solution. The stock cultures were grown in 25cm² flat bottles and the cell viability studies were carried out in 96 well microtiter plates.

Isolation and culturing of human PBMC: Human Peripheral Blood Mononuclear Cells (PBMC) mixtures of monocytes and lymphocytes were isolated by centrifugation method. Blood was diluted in PBS buffer in the ratio of 1:1 and this suspension was layered into histopaque-1077 and centrifuged (Harris 18/80, Sanyo, London UK,) for 30 minutes at 800 \times g and 4°C. PBMC were collected from the interface, lysed with 150 mM NH₄Cl and 10mM NaHCO₃. 0.1mM EDTA was maintained in RPMI-1640 medium. The cells were grown in RPMI-1640 medium containing 10% fetal calf serum (FCS). The medium was supplemented with glutamine (2mM), HEPS (20 mM), streptomycin (10,000µg/ml), penicillin (10,000µg/ml) and sodium bicarbonate (24 mM). Cells were grown in 25 ml flasks containing 12×10⁶ cells/ml. The cells were kept in a humidified atmosphere at 37 °C containing 5% CO₂. Cells were used at 2×10^6 cells/ml.

Both PBMC and MCF-7 cells were treated with various concentrations (10-50 μ g dissolved in DMSO) with and without extract for 24 hours of incubation. The final concentration of DMSO in the culture medium was monitored not to exceed to 0.05% in order to avoid toxicity of the cells.

In vitro Cytotoxicity by MTT assay: The assay was designed as per the procedure described earlier. In this assay, by the action of mitochondrial reductase, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a water-soluble dye is converted into insoluble formazan having purple colour. The cells are then treated with an organic solvent such as DMSO used for solubilizing the cells.

Different concentrations of the oil ranging as 20µl, 40µl 80µl and 160µl were subjected for the *in vitro* analysis against MCF7 cells and Peripheral Blood Mononuclear Cells (PBMC). Constant cell number was maintained in PBMC. During this process, the tetrozolium compound MTT was reduced by mitochondrial dehydrogenase as a result of which the colour gets changed to purple.

Lysing solution like organic solvent was added to the wells to solubilize the formazan crystals. ELISA reader (E1x 800 ELISA reader, Biotech Instruments Inc., USA) was used to measure the absorbance and the absorbane was measured at 570 nm. The data was analyzed by plotting absorbance versus cell number in a graph. The rate of reduction of tetrozolium salt is directly proportional to the rate of cell proliferation. The percentage of cytotoxicity was calculated by the formula [(A-B)/A×100] where A and B are the absorbance of control and treated cells respectively. The IC₅₀ value was found. The results were determined by performing in triplicates for each extract.

Statistic analysis: Results are summarized as means \pm S.E. of experiments. Comparison with essential oil and control of *Coleus zeylanicus* was observed by Analysis of Variance (ANOVA). Using the Tukey Kramer's test (INStat Graph Pad Software, Inc.,) significant differences were analyzed.

Results

MTT assay for cytotoxicity of the extracts with PBMC and MCF-7cells: MTT results against cancer cell lines MCF 7 and PBMC showed that as the concentration of oil increased the viability of cells decreased and it inhibited the proliferation of cells.

Optical microscope was used to analyze the cytopathic effect

of the plant extract on MCF 7 cells. Cells which were not treated were observed to be elongated and attached smoothly on the surface of the culture. Some of the cells were found to form groups called colonies. After treating the cells with extracts for 24h, the cells were found to be round and lost cell contacts. Surface morphological changes causing cell detachment were observed. From this study it is clear that crude extracts obtained from the leaves of *Coleus zeylanicus* have efficient anticancer activity against the cell lines of breast cancer.

GC-MS spectrum summary: Bioactive compounds present in the extract of *Coleus Zeylanicus* were identified through GC-MS. The parameters such as area (%), molecular weight (MW), molecular formula (MF), retention time (RT), synonym, peak and structure were identified. 12 compounds were observed and their structures are tabulated in table 2. The physiochemical properties and structure compounds were obtained from PubChem database.



Figure 1: MTT assay was used to evaluate the cytotoxic activity of *C.zeylanicus* leaf extract on MCF7 and PBMC cells. The IC50 values of the extracts were found to be 64.81 ± 0.57 μg/ml and 87.92 ± 0.86μg/ml respectively. The chloroform extract has showed effective cytotoxicity, (p<0.001) (Table 1). The IC50 of (positive control) doxorubicin was found to be 1.09±0.05 μg/ml. the positive correlation between the concentration of the oil and cytotoxicity when the regression analysis showed above 0.9. Extract of transferred plant showed higher toxic profile than non-transferred plant

 Table 1

 Effect of crude extract/positive control against PBMC and MCF-7 cell line by MTT assay

Name of the extract	IC50 value (µg/ml)				
Doxorubicin (Positive control)	1.09 ± 0.05				
Coleus zeylanicus (PBMC)	87.92 ± 0.86				
Coleus zeylanicus (MTT)	64.81 ± 0.57				



Figure 2: The collection five fractions from Column Chromatography were characterized on pre-coated plate in order to explore and elucidate the isolated compound structure



Figure 3: NMR Spectrum of fraction 4. Cubenol -¹H NMR (400 MHz, CD₃OD): δ H 0.76 (d, *J* = 6.7, CH₃-12 0.81 (d, *J* = 6.8, CH₃-13), 0.94 (d, *J* = 6.7, CH₃-15), 1.04 (m, CH₂-4), 1.25 (m, CH₂-7), 1.32 (m, CH₂-8), 1.23 (m, H-9), 1.46 (m, H-6), 1.64 (s, CH₃-14), 1.76 (m, H-11), 1.91 (m, CH₂-3), 2.05 (m, H-10), 5.35 (m, H-1). Widdrene - ¹H NMR (400 MHz, CD₃OD): δ 0.45 (2H, 0.39 (dd, *J* = 9.6, 8.1 Hz), 0.41 (dd, *J* = 9.6, 7.2 Hz)), 0.97-0.98 (6H, 0.97 (s), 0.97 (s)), 1.01 (3H, s), 1.18 (1H, dd, *J* = 8.1, 7.2 Hz), 1.38 (1H, ddd, *J* = 13.2, 10.3, 2.6 Hz), 1.31-1.54 (2H, 1.38 (ddd, *J* = 13.2, 10.3, 2.5 Hz), 1.49 (ddd, *J* = 13.2, 3.0, 2.6 Hz)), 1.46-1.72 (6H, 1.67 (s), 1.62 (ddd, *J* = 13.2, 3.0, 2.6 Hz), 1.52 (dtt, *J* = 13.1, 3.0, 2.5 Hz), 1.62 (dtt, *J* = 13.1, 10.3, 2.6 Hz)), 2.07 (1H, dd, *J* = 14.9, 9.8 Hz), 2.40 (1H, dd, *J* = 14.9, 9.5 Hz), 5.41 (1H, dd, *J* = 9.8, 9.5 Hz). Phytol - ¹H NMR (400 MHz, CD₃OD): δ 0.45 (2H, 0.39 (dd, *J* = 9.6, 7.2 Hz)), 0.98 (6H, 0.97 (s), 0.96 (s)), 1.0 (3H, s), 1.18 (1H, dd, *J* = 8.1, 7.2 Hz), 1.39 (1H, ddd, *J* = 13.1, 10.2, 2.6 Hz), 1.54 (2H, 1.38 (ddd, *J* = 13.2, 10.3, 2.5 Hz)), 0.98 (6H, 0.97 (s), 0.96 (s)), 1.0 (3H, s), 1.18 (1H, dd, *J* = 8.1, 7.2 Hz), 1.39 (1H, ddd, *J* = 13.1, 10.2, 2.6 Hz), 1.54 (2H, 1.38 (ddd, *J* = 13.2, 10.3, 2.5 Hz)), 0.98 (6H, 0.97 (s), 0.96 (s)), 1.0 (3H, s), 1.18 (1H, dd, *J* = 8.1, 7.2 Hz), 1.39 (1H, ddd, *J* = 13.1, 10.2, 2.6 Hz), 1.54 (2H, 1.38 (ddd, *J* = 13.2, 10.3, 2.5 Hz), 1.49 (ddd, *J* = 13.2, 3.0, 2.6 Hz)), 1.72 (6H, 1.67 (s), 1.62 (ddd, *J* = 13.2, 3.0, 2.6 Hz), 1.54 (2H, 1.38 (ddd, *J* = 13.2, 10.3, 2.5 Hz), 1.49 (ddd, *J* = 13.2, 3.0, 2.6 Hz)), 1.72 (6H, 1.67 (s), 1.62 (ddd, *J* = 13.2, 3.0, 2.6 Hz)), 1.54 (2H, 1.38 (ddd, *J* = 13.2, 10.3, 2.5 Hz), 1.49 (ddd, *J* = 13.2, 3.0, 2.6 Hz)), 1.72 (6H, 1.67 (s), 1.62 (ddd, *J* = 13.2, 3.0, 2.6 Hz)), 1.54 (2H, 1.38 (ddd, *J* = 13.2, 10.3, 2.5 Hz), 1.49 (ddd, *J* = 13.2, 3.0, 2.6 Hz)), 1.72 (6H, 1.67 (s), 1.62 (ddd, *J* = 13.2, 3.0, 2.6 Hz)), 1.54 (2H,

(2H, 1.38 (ddd, J = 13.2, 10.3, 2.5 Hz), 1.49 (ddd, J = 13.2, 3.0, 2.6 Hz)), 1.72 (6H, 1.67 (s), 1.62 (ddd, J = 13.2, 3.0, 2.6 Hz), 1.52 (dtt, J = 13.1, 3.0, 2.5 Hz), 1.62 (dtt, J = 13.1, 10.3, 2.6 Hz)), 2.07 (1H, dd, J = 14.9, 9.8 Hz), 2.40 (1H, dd, J = 14.9, 9.5 Hz), 5.41 (1H, dd, J = 9.8, 9.5 Hz)

Protein Targets for Molecular docking: Molecular Docking was done with the vascular endothelial growth factor D, crystal structure of VEGFR2 and target protein BCL-2 apoptosis regulatoras which play important role in cell initiation and cell signaling in cancer.

Docking results: Tables 4 to 7 provide the results from docking of the drug like compounds with the receptor GL. The majority of the reactions were observed to hydrophobic in nature except hydrogen bonds present in levomenol and phytol.

Drug likeness: LogP is responsible for analog optimization and drug selection. Hence drugs are screened according to logP than other criterias. Lipophility plays a major role in determining absorption, distribution, penetration across vital membranes, metabolism and elimination (ADME). LogP of the drug compound for oral administration should follow some of the Lipinski's rule:

- 1. The size must be less than 5 (<5)
- 2. Molecular weight of the compound must be between 150 and 500 g/mol
- 3. polarity: TPSA between 20 and 130 Å
- 4. Solubility: The value of log *S* must not be higher than 6
- 5. Flexibility: It should not have more than 9 rotatable bonds.

SWISSADME was performed to identify the drug likeness and the results are tabulated in table 8. From the result it is clear that all compounds show LogS value less than 6 and LogP values not higher than 5.

 Table 2

 GC-MS chromatogram represented bioactive compounds present in the leaf extracts of Coleus Zeylanicus.

S.N.	Phyto-Compounds	Phyto-Compounds Molecular weight (g/mol)		RT	Formula
1	GAMMA-GURJUNENE	204.35	100	6.6	$C_{15}H_{24}$
2	GAMMA-PATCHOULENE	204.35	66.83	5.2	$C_{15}H_{24}$
3	LEVOMENOL	222.37	31.99	6.7	$C_{15}H_{26}O$
4	CUBENOL	222.37	23.47	6.6	$C_{15}H_{26}O$
5	WIDDRENE	204.35	18.42	6.5	$C_{15}H_{24}$
6	GAMMA-HIMACHALENE	204.35	17.31	5	$C_{15}H_{24}$
7	BETA-YLANGENE	204.35	16.43	5.3	$C_{15}H_{24}$
8	ALPHA-BERGAMOTENE	204.35	16.2	4.7	$C_{15}H_{24}$
11	JUNIPENE	204.35	9.31	4.6	C15H24
12	PHYTOL	296.5	6.15	14.1	$C_{20}H_{40}O$

Table 3Protein targets for molecular docking study

S.N.	Target	PDB ID	Protein Target
1.	VEGF Receptor	<u>1Y6A</u>	Crystal structure of VEGFR2
2.	BCL-2	<u>5JSN</u>	Apoptosis regulator
3.	VEGF factor D	<u>2xv7</u>	Vascular Endothelial Growth Factor D

 Table 4

 Molecular docking of compounds with receptor 6GL8

Compounds Binding Energy		Inhibition Constant	Inter molecular energy	Internal Energy	Torsional Energy	Cluster RMS	Ref RMS
Cubenol	-6.51	16.78 µM	-7.11	-0.26	0.6	-0.26	19.62
Gamma Gurjunene	-6.4	20.22 µM	-6.7	-0.24	0.3	-0.24	19.17
Gamma Patchouline	-6.46	18.41 µM	-6.46	0	0	0	18.3
Widderine	-5.13	172.67 μM	-5.13	0	0	0	15.06
Phytol	-4.19	851.17 μM	-8.36	-1.19	4.18	-1.19	7.18
Ylangene	-6.65	13.34 µM	-6.95	-0.37	0.3	-0.37	18.42
Alphabergamotene	-6.22	27.71 μM	-7.11	-0.78	0.89	-0.78	18.51
Junipene	-7.13	5.97 µM	-7.13	0	0	0	17.83
Levomenol	-6.17	29.96 µM	-7.66	-0.5	1.49	-0.5	19.21

		0	-	-			
Compounds	Binding	Inhibition	Inter	Internal	Torsional	Cluster	Ref
	Energy	Constant	molecular	Energy	Energy	RMS	RMS
			energy				
Gamma Gurjunene	-6.5	17.3 µM	-6.79	-0.24	0.3	0.1	34.43
Gamma Patchoulene	-6.51	17.02 µM	-6.51	0	0	0	32.73
Levomenol	-6.09	34.46 µM	-7.58	-0.52	1.49	0	34.76
Cubenol	-6.37	21.37 µM	-6.97	-0.22	0.6	0	32.13
Widdrene	-6.12	32.7 µM	-6.12	0	0	0	46.04
Gamma Himachalene	-6.25	26.43 µM	-6.25	0	0	1.21	32.89
Beta Ylangene	-6.49	17.45 μM	-6.79	-0.26	0.3	0	34.94
Alpha Bergamotene	-6.18	29.5 µM	-7.08	-0.46	0.89	0	60.48
Alpha Guaiene	-6.57	15.39 µM	-6.86	-0.22	0.3	0.1	33.96
Alpha Panasinsene	-6.03	37.87 µM	-6.03	0	0	0	32.8
Junipene	-6.53	16.27 μM	-6.53	0	0	0	32.93
Phytol	-4.1	989.97 μM	-8.27	4.18	4.18	0	42.5
Beta Elemene	-6.12	32.54 µM	-7.02	0.89	0.89	0	34.29

 Table 5

 Molecular docking of compounds with receptor 1Y6A

Table 6	
Molecular docking of compounds with receptor 5JS	SN

Compounds	Binding	Inhibition	Inter	Internal	Torsional	Cluster	Ref
	Energy	Constant	molecular	Energy	Energy	RMS	RMS
			energy				
Gamma Gurjunene	-6.6	14.64 µM	-6.89	-0.25	0.3	0.03	55.65
Gamma Patchoulene	-5.99	40.49 µM	-5.99	0	0	0	61.37
Levomenol	-5.47	97.1 μM	-6.93	-0.86	1.49	0	54.88
Cubenol	-5.91	46.76 µM	-6.3	-0.22	0.6	0	47.48
Widdrene	-6.16	30.65 µM	-6.16	0	0	0	53.91
Gamma	-6.14	31.81 µM	-6.13	0	0	0.02	55.08
Himachalene							
Beta Ylangene	-6.29	24.59 µM	-6.59	-0.29	0.3	0.02	53.22
Alpha Bergamotene	-5.8	56.1 µM	-6.69	-0.57	0.89	0	54.6
Alpha Guaiene	-6	40.18 µM	-6.29	-0.22	0.3	0	53.76
Alpha Panasinsene	-6.12	32.55 µM	-6.12	0	0	0	62.6
Junipene	-6.17	30.12 µM	-6.17	0	0	0.08	53.56
Phytol	-4.66	380.68 µM	-8.82	-1.42	4.18	0	55.56
Beta Elemene	-5.65	72.77 μM	-6.54	-0.54	0.89	0	54.6

The molecular weight of the compounds was found to be less than 500g/mol with rotatable bonds less than 9 except for phytol. From this result it is observed that except phytol all the other compounds contain drug like properties. These compounds except phytol can be analyzed at *in vitro* level.

Minimum binding energy showing compounds: Docking was performed for each molecule with 3 targets and the results were evaluated based on number of hydrogen bonds formed, binding efficiency which provides fundamental information about the interaction and its efficiency.

ADME Properties analysis: 3 molecules namely cubenol, widdrene, phytol were subjected to SWISS ADME

bioinformatic tools to check biological and physical properties and results were evaluated [Table 8].

Only one compound CUBENOL was found to show all physical and biological properties when three compounds were tested on considering different parameters and this can be further used for treating cancer.

Discussion

Cancer is group of diseases which is widely being investigated and classified as many types based on different parameters such as part of body, type of tissue affected etc. Cancer is a disease which is characterized by uncontrolled or abnormal cell growth which has potential to spread and invade into different parts of body.



Figure 4: Apoptosis regulator Bcl-2 in complex with Cubenol

in the second decising of compounds with receptor 211 /									
Compounds	Binding	Inhibition	Inter	Internal	Torsional	Cluster	Ref		
-	Energy	Constant	molecular	Energy	Energy	RMS	RMS		
			energy						
Gamma Gurjunene	-5.97	42.13 µM	-6.27	-0.24	0.3	0	38.99		
Gamma Patchoulene	-5.98	41.33 µM	-5.98	0	0	0.06	40.71		
Levomenol	-5.32	126.72 µM	-6.81	-0.59	1.49	0	39.7		
Cubenol	-5.83	53.1 µM	-6.43	-0.26	0.6	0	41.21		
Widdrene	-5.37	116.21 μM	-5.37	0	0	0	41.59		
Gamma Himachalene	-5.99	40.88 µM	-5.99	0	0	0	40.21		
Beta Ylangene	-6.42	19.78 µM	-6.72	-0.29	0.3	0	39.99		
Alpha Bergamotene	-5.69	67.8 μM	-6.58	-0.5	0.89	0	40.05		
Alpha Guaiene	-5.37	115.76 μM	-5.67	-0.23	0.3	0.05	40.22		
Alpha Panasinsene	-5.98	41.64µM	-5.98	0	0	0.01	41.01		
Junipene	-5.43	104.56 µM	-5.43	0	0	0.04	40.98		
Phytol	-3.23	4.29µM	-7.41	-1.04	4.18	0	40.56		
Beta Elemene	-4.87	271 µM	-5.76	-0.6	0.89	0	40.62		

Table 7Molecular docking of compounds with receptor 2XV7

 Table 8

 SWISSADME for identifying drug likeliness of compounds

Compounds	Smiles Notation I		LogS	BBB	Lipinski	Mol.Wt	TPSA	Rotatable
_		_	_	Permeant	Score	(g/mol)		bonds
Cubenol	CC1CCC(C2C1(CCC(=C2)C)O)C(C)C	3.52	-3.48	Yes	Yes	222.22	20.23	1
Gamma Gujurene	CC1CCC(C2C1(CCC(=C2)O)C(C)C	4.33	-4.36	No	Yes:1	204.19	0	1
Levomenol	OC(CCC=C(C)C)(C)C1CCC(C)=CC1	3.76	-3.34	Yes	Yes	222.2	20.23	4
Widderine	C123C(C(C)=CCC1(C)CCCC3(C)C2	4.48	-4.11	No	Yes:1	204.19	0	0
Gamma	C123C(C)(C)C(CCC3=C)CC1C(C)C2	4.48	-4.26	No	Yes:1	204.19	0	0
Patcholene								
Phytol	CC(C)CCCC(C)CCCC(C)CCCC(=CCO)C	6.22	-5.98	No	Yes:1	296.53	20.23	13
Ylangene	CC1=CCC2C3C1C2(CCC3C(C)C)C	4.3	-3.86	Yes	Yes:1	204.35	0	1
Alphabergamotene	CC1=CCC2CC1C2(C)CCC=C(C)C	4.7	-4.97	No	Yes:1	204.35	0	3
Junipene	CC1(CCC2(C3C1(C2=C)CC3)C)C	4.5	-4.31	No	Yes:1	204.35	0	0



Figure 5: Apoptosis regulator Bcl-2 in complex with Widdrene



Figure 6: VEGFR2 Crystal structure in complex with Widdrene

S.N.	Target	Phytochemicals	Minimum binding energy	No. of Hydrogen Bonds
1	5JSN	CUBENOL	-5.91	1
		WIDDRENE	-6.16	1
2	2XV7	CUBENOL	-5.83	1
		WIDDRENE	-5.37	1
		PHYTOL	-3.23	1
3	1Y6A	WIDDRENE	-6.12	1
		PHYTOL	-4.1	2

 Table 9

 Binding efficiency of interacted molecules



Figure 7: VEGFR2 Crystal structure in complex with Phytol



Figure 8: Vascular Endothelial Growth Factor D in complex with Cubenol

		0	•			-	•		
Molecule	Mol. Wt	TPSA	Consensus	Solubility	GI	BBB	Log	Lipinski	Lead
			Log P		absorption	Permeant	Кр		Likeness
			-		-		(cm/s)		
Cubenol	222.37	20.23	3.52	Soluble	High	Yes	-5.03	0	2
Widdrene	204.35	0	4.48	Moderate	Low	No	-4.17	1	2
				soluble					
Phytol	296.53	20.23	6.22	Poorly	Low	No	-2.29	1	2
				soluble					

 Table 10

 Biological and Physical properties of widdrene, cubenol and phytol



Figure 9: VEGFR2 Crystal structure in complex with Widdrene



Figure 10: VEGFR2 Crystal structure in complex with Phytol

It has been most leading diseases over past few years. More than 100 types of cancers have been discovered and yet more types are to be discovered. Some cancers are genetic and some are hereditary (ovarian, breast cancers).

Treatment of this disease is possible with one form of anticarcinogen or combination. Chemotherapy, radiation therapy, surgical process, immunotherapy, targeted therapy, or hormone therapy are available treatment for cancer. Various anti-cancer drugs have been found from the past decades from medicinal plants and reported high response towards cancer inhibitory action studied by *in vitro* and *in vivo* approach. Research is still going on for the finding of potential anti-cancer candidates. Phytochemicals with anticancer ability have been extracted from various medicinal plant species and being tested as targets for cancer. Thousands of phytochemicals have reported high potential for some cancer targets and used as candidate drug molecules for anticancer therapeutic approach with lesser side effects.

In this study we have focused on phytochemicals extracted from plant species *Coleus Zeylanicus* and these plant compounds have been cited known for their various biological activities.^{8,10,13} GC-MS spectrum of leaves extract of *Coleus Zeylanicus* revealed the presence of 12 phytocompounds that belong to flavonoids, carbohydrates, anthocyanin, tannins, phenols, alkaloids, steroids classes. These bioactive compounds could be a reason for the anticancer activity of leaf extracts of *Coleus Zeylanicus*. In referencing supports of this study, earlier some studies have been reported the potential antimicrobial activities of essential oil isolated from *Coleus Zeylanicus*. In addition, we have also investigated the *in silico* anti-cancer activity of leaves extract of *Coleus Zeylanicus*.

The above study evidences that *Coleus Zeylanicus*, plant enriched with various potential bioactive compounds could be potent pharmacological drug candidates having inhibitory actions like anti-microbial, anti-cancer, anti-oxidant, antiinflammatory etc. Hence, the identification of phyto constituents from *Coleus Zeylanicus* is considered to be a significant medicinal activity and further studies including single compound purification and investigation of biological properties will be future bioprospecting to be studied in future.

Conclusion

Based on the obtained results, in which *in vitro* anti-cancer activity, PBMC and MCF-7 cell line models were used, it can be concluded that the leaves extract of *Coleus zeylanicus* possesses significant anti-cancer bioactivity for further extensive future work.

References

1. Babior B.M., Phagocytes and oxidative stress, *Am J Med.*, **109**, 33–44 (**2000**)

2. Babu N., Raja S., Albert S., Ignacimuthu S. and Dorn S., Comparative efficacy of some indigenous plant extracts against the pulse beetle Callosobruchus maculates F. (Coleoptera: Bruchidae), *Biol Agric Hortic*, **17**, 145-50 (**1999**)

3. Dissanayaka M.D. and Fosberg F.R., A Revised Hand Book to the Flora of Ceylon, Smithosan Institute and National Science Foundation, Washington D.C., New Delhi, Amerind Publishing Co. Pvt. Ltd., 150-1151 (**1981**)

4. Priti, Battan Bindu and Rani Sulekha, Evaluation of Antimicrobial activity of Bacterial Endophytes isolated from Tinospora cordifolia, *Res. J. Biotech.*, **15**(4), 9-18 (**2020**)

5. Kotagiri Divya, Shaik Khasim Beebi and Kolluru Viswanatha Chaitanya, Antimicrobial and Antioxidant Properties of Essential Oil Isolated from Coleus zeylanicus under Normal and Salinity Stress Conditions, Free Radicals, Antioxidants and Diseases, Rizvan Ahmad, Intech Open, DOI: 10.5772/intechopen.73966 (2018)

6. Doll R. and Peto R., 4th ed., USA, Oxford University Press, Malignant diseases, Text Book of Medicine, 483–4 (**2003**)

7. Rasineni Girish K., Siddavattam Dayananda and Reddy Attipalli R., Free radical quenching activity and polyphenols in three species of Coleus (**2008**)

8. Janssen A.M., Schffer J.J. and Sveden B.A., Antimicrobial activity of essential oils: 1976-1986 literature review, Aspects of the test methods, *Planta Medica*, **53**, 395-398 (**1987**)

9. Jayaweera D.M.A., Medicinal plants, National Science Council of Sri Lanka (**1982**)

10. Kelloff G.J., Perspectives on cancer chemoprevention research and drug development, *Adv Cancer Res.*, **78**, 199–334 (**2008**)

11. Lakshmi M. and Nandagopal S., Antimicrobial efficacy and phytochemical constituents of essential oil on Coleus zeylanicus (Benth.) L.H. Cramer a valuable medicinal plant, *Der Pharm Lett*, **9**, 29-39 (**2017**)

12. Nipun D., Vijay S., Jaykumar B., Kirti S.P. and Richard L., Antitumor Activity of *Dendrophthoe falcata* against Ehrlich Ascites Carcinoma in Swiss Albino Mice, *Pharma Crops*, **2**, 1–7 (**2011**)

13. Soliman A.S., Samad S., Banerjee M., Chamberlain R.M., Robert M. and Aziz Z., Brief Continuing Medical Education (CME) Module Raises Knowledge of Developing Country Physicians International Electronic, *J Health Educ.*, **9**, 31–41 (2006).

(Received 28th January 2021, accepted 05th March 2021)